{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:27:52Z","timestamp":1791563272640,"version":"4.3.4"},"reference-count":320,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":67,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.gastrohep.2023.10.009","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T11:59:39Z","timestamp":1705319979000},"page":"401-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH\u2013AEG\u2013SEPD\u2013SEOM\u2013GETECCU"],"prefix":"10.1016","volume":"47","author":[{"given":"Mar","family":"Riveiro-Barciela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Carballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"D\u00edaz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00edriam","family":"Ma\u00f1osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gallego-Plazas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Cubiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jim\u00e9nez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mench\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mesonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Rodr\u00edguez-Gand\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Carlota","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2023.10.009_bib1000","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ciresp.2013.08.002","article-title":"GRADE system: classification of quality of evidence and strength of recommendation","volume":"92","author":"Aguayo-Albasini","year":"2014","journal-title":"Cir Esp"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1010","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep: Innov Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1015","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1020","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1025","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1030","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.livres.2021.01.003","article-title":"Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: a nationwide hospitalization analysis","volume":"5","author":"Weissman","year":"2021","journal-title":"Liver Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1040","doi-asserted-by":"crossref","first-page":"650292","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1045","doi-asserted-by":"crossref","first-page":"e0253070","DOI":"10.1371\/journal.pone.0253070","article-title":"Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy","volume":"16","author":"Cunningham","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1050","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1055","unstructured":"Institute USDoHaHSNNC. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03."},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1060","doi-asserted-by":"crossref","first-page":"e19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1065","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1075","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1080","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1085","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1159\/000518104","article-title":"Immune checkpoint inhibitors: the emerging cornerstone in cholangiocarcinoma therapy?","volume":"10","author":"Guti\u00e9rrez-Larra\u00f1aga","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1100","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211039952","article-title":"Application of immune checkpoint inhibitors in the treatment of cholangiocarcinoma","volume":"20","author":"Zeng","year":"2021","journal-title":"Technol Cancer Res Treat"},{"issue":"4 Suppl","key":"10.1016\/j.gastrohep.2023.10.009_bib1105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1110","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2019.37.4_suppl.387","article-title":"Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)","volume":"37","author":"Ioka","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1120","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1125","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1130","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1140","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs \u2013 I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1150","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3390\/cancers12113446","article-title":"RETOINMUNO multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors","volume":"12","author":"Londo\u00f1o","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1155","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cld.2007.06.012","article-title":"Cancer chemotherapy II: atypical hepatic injuries","volume":"11","author":"Rodriguez-Frias","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1165","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0034-1375957","article-title":"Drug-induced liver injury due to cancer chemotherapeutic agents","volume":"34","author":"Bahirwani","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.15403\/jgld-3207","article-title":"Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors","volume":"30","author":"Riveiro-Barciela","year":"2021","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1175","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2020.02.004","article-title":"Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report","volume":"31","author":"Charvet","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1180","first-page":"9","article-title":"Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)","author":"Gonzalez-Cao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1185","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1190","doi-asserted-by":"crossref","first-page":"916213","DOI":"10.3389\/fmed.2022.916213","article-title":"The low incidence of viral hepatitis reactivation among subjects on immunotherapy reduces the impact of suboptimal screening rate","volume":"9","author":"Aceituno","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.gastrohep.2019.09.006","article-title":"Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH","volume":"42","author":"Bataller","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1200","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1210","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1220","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2021.04.045","article-title":"Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy","volume":"153","author":"Dearden","year":"2021","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1225","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1235","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.gastrohep.2020.07.009","article-title":"Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: a descriptive observational study","volume":"44","author":"Sanz-Segura","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1240","doi-asserted-by":"crossref","first-page":"101491","DOI":"10.1016\/j.clinre.2020.06.016","article-title":"Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal","volume":"45","author":"Gauci","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1245","doi-asserted-by":"crossref","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","article-title":"A multicenter characterization of hepatitis associated with immune checkpoint inhibitors","volume":"10","author":"Patrinely","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1250","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.medcli.2020.06.057","article-title":"Toxicities from immunotherapy: from clinical trials to real-world clinical practice","volume":"155","author":"Riveiro-Barciela","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1255","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/jgh.14889","article-title":"Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor","volume":"35","author":"Sawada","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","article-title":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"130","author":"Romanski","year":"2020","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1270","first-page":"78","article-title":"A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors","author":"Riveiro-Barciela","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1275","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1280","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies?","volume":"70","author":"Riveiro-Barciela","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1285","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1290","first-page":"407","article-title":"Overview of newer glucocorticosteroid preparations for inflammatory bowel disease","volume":"4","author":"Brattsand","year":"1990","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1295","doi-asserted-by":"crossref","first-page":"102460","DOI":"10.1016\/j.autrev.2020.102460","article-title":"Characterization of auto-immune hepatitis associated with the use of anti-TNF\u03b1 agents: an analysis of 389 cases in VigiBase","volume":"19","author":"Vollmer","year":"2020","journal-title":"Autoimmunity Rev"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1300","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1305","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bulcan.2020.04.019","article-title":"Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab","volume":"107","author":"Bouhlel","year":"2020","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1310","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1315","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors","volume":"12","author":"Shimozaki","year":"2020","journal-title":"Cancer Manage Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1320","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1325","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00262-016-1926-2","article-title":"Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series","volume":"66","author":"Spain","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1330","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1335","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1340","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1345","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Internatl"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1350","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1002\/cncr.33165","article-title":"Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1355","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study","volume":"21","author":"Riveiro-Barciela","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1365","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.10.011","article-title":"Long-term sequelae of drug-induced liver injury","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MOG.0000000000000813","article-title":"Drug-induced bile duct injury: new agents, new mechanisms","volume":"38","author":"Scoazec","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1375","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1380","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1385","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1390","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1395","first-page":"14","article-title":"Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab","author":"Suda","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1400","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s12328-020-01218-0","article-title":"A rare case of immunotherapy-induced cholangitis and gastritis","volume":"13","author":"Fujii","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1405","doi-asserted-by":"crossref","first-page":"100270","DOI":"10.1016\/j.ctarc.2020.100270","article-title":"Atezolizumab-induced sclerosing cholangitis in a patient with lung cancer: a case report","volume":"26","author":"Nabeshima","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1410","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","article-title":"A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event","volume":"36","author":"Gelsomino","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1415","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.cgh.2020.11.048","article-title":"Pembrolizumab-induced sclerosing cholangitis","volume":"20","author":"Tahboub Amawi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1420","first-page":"12","article-title":"Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis","author":"Williams","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1425","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12328-020-01287-1","article-title":"A case with life-threatening secondary sclerosing cholangitis caused by nivolumab","volume":"14","author":"Yoshikawa","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1430","doi-asserted-by":"crossref","first-page":"e241700","DOI":"10.1136\/bcr-2021-241700","article-title":"Sclerosing cholangitis in a patient treated with nivolumab","volume":"14","author":"Talbot","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1435","first-page":"439","article-title":"Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature","volume":"11","author":"Izumi","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1440","doi-asserted-by":"crossref","first-page":"e25774","DOI":"10.1097\/MD.0000000000025774","article-title":"A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy","volume":"100","author":"Hirasawa","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1445","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jgh.14136","article-title":"Hepatobiliary and pancreatic: nivolumab-related cholangiopathy","volume":"33","author":"Hamoir","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1450","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s12328-020-01178-5","article-title":"Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report","volume":"13","author":"Sato","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1455","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2217\/imt-2019-0077","article-title":"Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma","volume":"11","author":"C\u01celug\u01cereanu","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1460","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2169\/internalmedicine.2330-18","article-title":"Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature","volume":"58","author":"Sawada","year":"2019","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1465","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1470","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.31089","article-title":"Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma","volume":"71","author":"Stuart","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1475","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.jtho.2019.04.023","article-title":"Nivolumab-induced secondary sclerosing cholangitis with deterioration despite immunosuppression","volume":"14","author":"Anderson","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1480","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1485","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/14712598.2020.1762562","article-title":"Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience","volume":"20","author":"Vitale","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1490","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s10637-021-01136-z","article-title":"Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis","volume":"39","author":"Takinami","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1495","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1500","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1505","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1510","first-page":"539","article-title":"A rare case of hepatic vanishing bile duct syndrome occurring after combination therapy with nivolumab and cabozantinib in a patient with renal carcinoma","volume":"12","author":"Gourari","year":"2022","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1515","first-page":"10339","article-title":"Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab","volume":"27","author":"Zhong","year":"2020","journal-title":"Can J Urol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1520","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/imt-2021-0078","article-title":"Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature","volume":"14","author":"Gemelli","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1525","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1530","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12328-022-01590-z","article-title":"Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case","volume":"15","author":"Kataoka","year":"2022","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1535","first-page":"101703","article-title":"Immunotherapy induced enterocolitis and gastritis \u2013 what to do and when? Best practice & research","volume":"48\u201349","author":"Cheung","year":"2020","journal-title":"Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1540","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1545","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti-CTLA-4 therapy","volume":"42","author":"Gupta","year":"2015","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1550","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1002\/cam4.2397","article-title":"Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control","volume":"8","author":"Hughes","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1555","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume":"14","author":"Verschuren","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1560","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1007\/s00261-019-02334-3","article-title":"Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy","volume":"45","author":"Shieh","year":"2020","journal-title":"Abdom Radiol (New York)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1565","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1570","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1575","doi-asserted-by":"crossref","first-page":"e000278","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1580","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1585","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1590","first-page":"5","article-title":"Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma","author":"Favara","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1595","doi-asserted-by":"crossref","first-page":"e000451","DOI":"10.1136\/jitc-2019-000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1600","doi-asserted-by":"crossref","first-page":"e00249","DOI":"10.14309\/crj.0000000000000249","article-title":"Nivolumab-induced concomitant severe upper and lower gastrointestinal immune-related adverse effects","volume":"6","author":"Alhatem","year":"2019","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1605","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","article-title":"Ipilimumab-induced perforating colitis","volume":"47","author":"Mitchell","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1610","article-title":"Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma","volume":"2018","author":"Mohamed","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1615","doi-asserted-by":"crossref","first-page":"837","DOI":"10.21037\/apm-21-58","article-title":"Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report","volume":"11","author":"Trystram","year":"2022","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1620","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijscr.2020.12.096","article-title":"Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction \u2013 a case report","volume":"79","author":"Mourad","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1625","doi-asserted-by":"crossref","first-page":"e1524695","DOI":"10.1080\/2162402X.2018.1524695","article-title":"Clinical characterization of colitis arising from anti-PD-1 based therapy","volume":"8","author":"Wang","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1630","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.07.049","article-title":"Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: a retrospective cohort study","volume":"82","author":"Molina","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1635","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1177\/1078155220968909","article-title":"Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors","volume":"27","author":"Nice","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1640","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","article-title":"Emergency presentations in patients treated with immune checkpoint inhibitors","volume":"130","author":"Cooksley","year":"2020","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1645","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1650","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1655","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1660","doi-asserted-by":"crossref","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1665","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1670","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1675","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1680","unstructured":"Institute USDoHaHSNNC. Common terminology criteria for adverse events (CTCAE). Version 5.0. 2017."},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1685","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1690","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.3747\/co.27.6251","article-title":"The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"27","author":"Bishay","year":"2020","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1695","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1700","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1705","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1710","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1715","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des Dev Therapy"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1720","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40264-020-00979-4","article-title":"Ipilimumab-induced enterocolitis: a systematic review and meta-analysis","volume":"43","author":"Witges","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1725","doi-asserted-by":"crossref","first-page":"e001488","DOI":"10.1136\/jitc-2020-001488","article-title":"Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab","volume":"8","author":"Nahar","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1730","doi-asserted-by":"crossref","first-page":"Fso655","DOI":"10.2144\/fsoa-2020-0129","article-title":"Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review","volume":"7","author":"Schmerling","year":"2020","journal-title":"Future Sci OA"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1735","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1740","doi-asserted-by":"crossref","first-page":"103351","DOI":"10.1016\/j.critrevonc.2021.103351","article-title":"Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer","volume":"162","author":"Berti","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1745","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol (Lond, Engl)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1750","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00384-019-03268-4","article-title":"Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature","volume":"34","author":"Ca\u00f1ete","year":"2019","journal-title":"Int J Colorect Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1755","first-page":"291","article-title":"Incidence and risk of colitis with programmed death 1 versus programmed death ligand 1 inhibitors for the treatment of cancer","volume":"43","author":"Miyashita","year":"2020","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1760","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1765","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2147\/TCRM.S308194","article-title":"Adverse events induced by PD-1\/PD-L1 inhibitors: a real-world single-centre experience with a management-based approach","volume":"17","author":"Grimaud","year":"2021","journal-title":"Therap Clin Risk Manage"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1770","first-page":"699","article-title":"Histological diversity of anti-PD1-induced colitis","volume":"37","author":"Sakellariou","year":"2022","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1775","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1346-8138.14227","article-title":"Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: an interim analysis of a postmarketing surveillance","volume":"45","author":"Kiyohara","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1780","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1785","doi-asserted-by":"crossref","first-page":"621639","DOI":"10.3389\/fonc.2021.621639","article-title":"Treatment-related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review","volume":"11","author":"Ouyang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1790","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1795","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1800","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1805","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/TCRM.S193338","article-title":"Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients","volume":"15","author":"Zhou","year":"2019","journal-title":"Therap Clin Risk Manage"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1810","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1815","first-page":"Mmt01","article-title":"Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review","volume":"5","author":"Mearns","year":"2018","journal-title":"Melan Manage"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1820","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1825","first-page":"46","article-title":"Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis","volume":"34","author":"Shieh","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1830","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1835","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.06.093","article-title":"Insights from pharmacovigilance: gastrointestinal-related immune checkpoint inhibitor adverse events","volume":"159","author":"Reese","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1840","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1845","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/cncr.32966","article-title":"Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis","volume":"126","author":"Grover","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1850","doi-asserted-by":"crossref","first-page":"106770","DOI":"10.1016\/j.intimp.2020.106770","article-title":"Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens","volume":"87","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1855","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1860","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10mg\/kg versus ipilimumab 3mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1865","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1870","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192347","article-title":"Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer","volume":"40","author":"Shao","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1875","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fonc.2020.00197","article-title":"Risk of gastrointestinal adverse events in cancer patients treated with immune checkpoint inhibitor plus chemotherapy: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1880","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2020.00261","article-title":"The risk ratio of immune-related colitis, hepatitis, and pancreatitis in patients with solid tumors caused by PD-1\/PD-L1 inhibitors: a systematic review and meta-analysis","volume":"10","author":"Tian","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1885","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1890","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1895","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1900","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin Sarcom Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1905","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1910","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/2326-6066.CIR-13-0082","article-title":"Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma","volume":"1","author":"Barker","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1915","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1920","doi-asserted-by":"crossref","first-page":"101778","DOI":"10.1016\/j.clinre.2021.101778","article-title":"Immune checkpoint inhibitor induced colitis: a nationwide population-based study","volume":"46","author":"Farha","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1925","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1930","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1935","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10637-019-00845-w","article-title":"Germinal Immunogenetics predict treatment outcome for PD-1\/PD-L1 checkpoint inhibitors","volume":"38","author":"Refae","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1940","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00262-020-02797-0","article-title":"Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors","volume":"70","author":"Abdel-Wahab","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1945","doi-asserted-by":"crossref","first-page":"611012","DOI":"10.3389\/fonc.2021.611012","article-title":"Comparative efficacy and safety of immunotherapy alone and in combination with chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1950","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1955","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.21037\/tlcr-21-464","article-title":"Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system","volume":"10","author":"Bai","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1960","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1965","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdz224","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"30","author":"Chaput","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1970","doi-asserted-by":"crossref","first-page":"768957","DOI":"10.3389\/fimmu.2021.768957","article-title":"Mechanisms of immune checkpoint inhibitor-mediated colitis","volume":"12","author":"Westdorp","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1975","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1980","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s40425-019-0714-x","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1985","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1990","doi-asserted-by":"crossref","first-page":"585311","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events \u2013 a comprehensive review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib1995","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2000","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2005","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1111\/1759-7714.14063","article-title":"Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"12","author":"Fujimoto","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40425-018-0408-9","article-title":"A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab","volume":"6","author":"Friedlander","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2035","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1200\/JOP.19.00672","article-title":"Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis","volume":"16","author":"Grover","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2040","doi-asserted-by":"crossref","first-page":"e002567","DOI":"10.1136\/jitc-2021-002567","article-title":"Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study","volume":"9","author":"Sleiman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.16217","article-title":"Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases","volume":"53","author":"Meserve","year":"2021","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2050","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2055","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.gie.2019.09.009","article-title":"Immune checkpoint inhibitor-related luminal GI adverse events","volume":"90","author":"Kr\u00f6ner","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2060","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s10620-020-06441-w","article-title":"Clinical, endoscopic, and pathological characteristics of immune checkpoint inhibitor-induced gastroenterocolitis","volume":"66","author":"Hayashi","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S2468-1253(20)30014-5","article-title":"British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis","volume":"5","author":"Powell","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2070","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/apt.15263","article-title":"Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis","volume":"49","author":"Wright","year":"2019","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.14423\/SMJ.0000000000000944","article-title":"Flexible sigmoidoscopy rather than colonoscopy is adequate for the diagnosis of ipilimumab-associated colitis","volume":"112","author":"Herlihy","year":"2019","journal-title":"South Med J"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jgh.15691","article-title":"Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-mediated colitis: a cross-sectional study","volume":"37","author":"De Silva","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-017-2267-z","article-title":"Immune checkpoint inhibitor colitis: the flip side of the wonder drugs","volume":"472","author":"Assarzadegan","year":"2018","journal-title":"Virch Arch"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ecco-jcc\/jjab141","article-title":"ECCO topical review on clinicopathological spectrum and differential diagnosis of inflammatory bowel disease","volume":"16","author":"Feakins","year":"2022","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2095","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","article-title":"Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis","volume":"32","author":"Oble","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/his.13224","article-title":"Immune modulator-induced changes in the gastrointestinal tract","volume":"71","author":"Bavi","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2110","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/cas.14773","article-title":"Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis","volume":"112","author":"Kubo","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2120","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2125","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of \u2018immunomodulatory gastroenterocolitis\u2019","volume":"70","author":"Gonzalez","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2130","doi-asserted-by":"crossref","first-page":"e002058","DOI":"10.1136\/jitc-2020-002058","article-title":"Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/00365529609006407","article-title":"Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs","volume":"31","author":"Meling","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2140","first-page":"350","article-title":"Proton pump inhibitors may cause elevation in faecal calprotectin levels","volume":"66","author":"Cohen","year":"2016","journal-title":"Br J Gener Pract"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MOG.0000000000000593","article-title":"Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management","volume":"36","author":"Abu-Sbeih","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2150","doi-asserted-by":"crossref","first-page":"e001329","DOI":"10.1136\/jitc-2020-001329","article-title":"Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis","volume":"8","author":"Durbin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2155","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","author":"Kim","year":"2013","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2160","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00261-015-0560-3","article-title":"Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis","volume":"41","author":"Barina","year":"2016","journal-title":"Abdom Radiol (New York)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40134-017-0256-2","article-title":"Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy","volume":"5","author":"Widmann","year":"2016","journal-title":"Curr Radiol Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","article-title":"Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients","volume":"5","author":"Garcia-Neuer","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejca.2017.09.019","article-title":"Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis","volume":"86","author":"Franklin","year":"2017","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2185","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2190","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MIB.0000000000000602","article-title":"Gut microbiota dysbiosis as risk and premorbid factors of IBD and IBS along the childhood\u2013adulthood transition","volume":"22","author":"Putignani","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2195","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ecco-jcc\/jjaa036","article-title":"Ulcerative colitis and cytomegalovirus infection: from A to Z","volume":"14","author":"Mourad","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2200","first-page":"28","article-title":"Infectious colitis associated with ipilimumab therapy","volume":"7","author":"McCutcheon","year":"2014","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2205","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/COC.0000000000000841","article-title":"Outcomes of immune checkpoint inhibitor-related diarrhea or colitis in cancer patients with superimposed gastrointestinal infections","volume":"44","author":"Ma","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2210","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","article-title":"Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case\u2013control study","volume":"6","author":"Eshet","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2215","doi-asserted-by":"crossref","first-page":"e000958","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2220","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2225","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2230","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2022.40.16_suppl.4035","article-title":"Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648","volume":"40","author":"Chau","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2235","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1053\/j.gastro.2019.04.044","article-title":"Diarrhea in a patient receiving chemotherapy","volume":"157","author":"Majeed","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2240","doi-asserted-by":"crossref","first-page":"e240398","DOI":"10.1136\/bcr-2020-240398","article-title":"Amelanotic anorectal malignant melanoma in an ulcerative colitis patient: a rare coincidence or a rare association","volume":"14","author":"Kuriakose Kuzhiyanjal","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2245","first-page":"631","article-title":"Diagnosis and treatment of 41 patients with malignant peritoneal mesothelioma","volume":"26","author":"Zhang","year":"2004","journal-title":"Zhonghua zhong liu za zhi"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2250","first-page":"101","article-title":"Drug-induced pancreatic atrophy (\u201cthe vanishing pancreas\u201d)","volume":"10","author":"Khamaysi","year":"2020","journal-title":"Eur J Hepato-gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2255","doi-asserted-by":"crossref","first-page":"e231211","DOI":"10.1136\/bcr-2019-231211","article-title":"Acute kidney injury from immune checkpoint inhibitor use","volume":"12","author":"Gordon","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2260","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s12328-021-01459-7","article-title":"A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis","volume":"14","author":"Naito","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2265","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J Natl Compreh Cancer Netw"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1756283X16646709","article-title":"Ipilimumab-induced colitis: experience from a tertiary referral center","volume":"9","author":"O\u2019Connor","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2275","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3748\/wjg.v23.i11.2023","article-title":"Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis","volume":"23","author":"Jain","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2280","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1111\/ajco.12651","article-title":"Infliximab for ipilimumab-induced colitis: a series of 13 patients","volume":"13","author":"Hillock","year":"2017","journal-title":"Asia-Pac J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2285","first-page":"321","article-title":"Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis","volume":"24","author":"Minor","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2290","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","article-title":"Checkpoint inhibitor-induced colitis","volume":"115","author":"Bellaguarda","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2295","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/CMR.0000000000000543","article-title":"Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis","volume":"29","author":"Mir","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2300","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ibd\/izy240","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity?","volume":"25","author":"Choi","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2305","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2310","doi-asserted-by":"crossref","first-page":"1760676","DOI":"10.1080\/2162402X.2020.1760676","article-title":"Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors","volume":"9","author":"de Andrea","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2315","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2320","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","article-title":"Ipilimumab-induced acute severe colitis treated by infliximab","volume":"23","author":"Pag\u00e8s","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2330","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","article-title":"Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab","volume":"54","author":"Johnston","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4292\/wjgpt.v10.i1.29","article-title":"Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: a case report","volume":"10","author":"Nassri","year":"2019","journal-title":"World J Gastrointest Pharmacol Therap"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2340","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3892\/mco.2021.2227","article-title":"Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: a retrospective study","volume":"14","author":"Kadokawa","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2345","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/imj.14854","article-title":"Impending infliximab access crisis: a case of steroid-refractory, relapsing immunotherapy-induced colitis responsive to infliximab","volume":"50","author":"Connolly","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2350","doi-asserted-by":"crossref","first-page":"e1128611","DOI":"10.1080\/2162402X.2015.1128611","article-title":"Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis","volume":"5","author":"Lankes","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2355","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2360","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1158\/1078-0432.CCR-15-2471","article-title":"Infliximab for IPILIMUMAB-related colitis-letter","volume":"21","author":"Arriola","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2365","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2370","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2375","doi-asserted-by":"crossref","unstructured":"C\u00e9spedes Mart\u00ednez E, Robles Alonso V, Herrera-De Guise C, Mayorga L, Casellas F, Roca-Herrera M, et al. Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital. Revista espanola de enfermedades digestivas 2023.","DOI":"10.17235\/reed.2023.9436\/2022"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2380","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000507579","article-title":"Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course","volume":"5","author":"Burla","year":"2020","journal-title":"Inflam Intest Dis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2390","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5306\/wjco.v10.i10.350","article-title":"Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: a case report","volume":"10","author":"Randhawa","year":"2019","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2395","article-title":"Vedolizumab: a novel treatment for ipilimumab-induced colitis","volume":"2016","author":"Hsieh","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2400","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2405","doi-asserted-by":"crossref","first-page":"360","DOI":"10.12659\/AJCR.908570","article-title":"Resolution of infliximab-refractory nivolumab-induced acute severe enterocolitis after cyclosporine treatment in a patient with non-small cell lung cancer","volume":"19","author":"Iyoda","year":"2018","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2410","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2415","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMc2031717","article-title":"Ustekinumab for refractory colitis associated with immune checkpoint inhibitors","volume":"384","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2420","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2425","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.crohns.2014.06.009","article-title":"Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3)","volume":"8","author":"Loras","year":"2014","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2430","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.gastrohep.2013.01.002","article-title":"Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease","volume":"36","author":"Cabriada","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2020.02.014","article-title":"Successful management of refractory immune-mediated enterocolitis with cyclosporine","volume":"131","author":"Pes\u00e1ntez","year":"2020","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2440","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.14309\/ajg.0000000000002332","article-title":"IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience","volume":"118","author":"Shirwaikar Thomas","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2445","doi-asserted-by":"crossref","first-page":"e00946","DOI":"10.14309\/crj.0000000000000946","article-title":"Refractory checkpoint inhibitor colitis responsive to ustekinumab","volume":"9","author":"Perez Del Nogal","year":"2022","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2450","doi-asserted-by":"crossref","first-page":"e000989","DOI":"10.1136\/bmjgast-2022-000989","article-title":"Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report","volume":"9","author":"Holmstroem","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2455","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12328-023-01826-6","article-title":"Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways","volume":"16","author":"Sleiman","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2460","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2465","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2470","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2475","doi-asserted-by":"crossref","first-page":"730320","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2480","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2217\/imt-2020-0103","article-title":"Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis","volume":"12","author":"Park","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2485","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2018.10.006","article-title":"Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors","volume":"106","author":"de Malet","year":"2019","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2490","first-page":"8","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2495","doi-asserted-by":"crossref","first-page":"e002850","DOI":"10.1136\/jitc-2021-002850","article-title":"Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events","volume":"9","author":"Siddiqui","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2500","first-page":"41","article-title":"Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer","volume":"44","author":"Kartolo","year":"2021","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2505","first-page":"73","article-title":"Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial","volume":"35","author":"Thompson","year":"2012","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2510","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2515","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s12094-017-1817-9","article-title":"Top ten errors of statistical analysis in observational studies for cancer research","volume":"20","author":"Carmona-Bayonas","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2520","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2530","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2535","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2020.09.001","article-title":"Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1\/PD-L1 inhibitors alone and in combination with radiotherapy","volume":"140","author":"Schweizer","year":"2020","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2540","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2545","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2550","first-page":"A147","article-title":"PTU-061 immunotherapy-related gastritis in a tertiary oncology centre","volume":"68","author":"Cheung","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2555","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2560","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2565","first-page":"482","article-title":"Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient","volume":"83","author":"Vandepapeli\u00e8re","year":"2020","journal-title":"Acta Gastro-enterol Belg"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2570","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.14309\/crj.2017.57","article-title":"Severe esophagitis and gastritis from nivolumab therapy","volume":"4","author":"Boike","year":"2017","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2575","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2580","doi-asserted-by":"crossref","first-page":"383","DOI":"10.14740\/gr1068w","article-title":"An unusual case of gastritis in one patient receiving PD-1 blocking therapy: coexisting immune-related gastritis and cytomegaloviral infection","volume":"11","author":"Lu","year":"2018","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2585","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.clcc.2020.04.006","article-title":"Acute ulceronecrotic gastritis with cytomegalovirus reactivation: uncommon toxicity of immune checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer","volume":"19","author":"Hulo","year":"2020","journal-title":"Clin Colorect Cancer"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2590","article-title":"Pancreatitis and hyperlipasemia in the setting of immune checkpoint inhibitor therapy","volume":"21","author":"Townsend","year":"2023","journal-title":"J Natl Compreh Cancer Netw"},{"key":"10.1016\/j.gastrohep.2023.10.009_bib2595","doi-asserted-by":"crossref","first-page":"1166299","DOI":"10.3389\/fimmu.2023.1166299","article-title":"Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570523004557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570523004557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T21:30:27Z","timestamp":1717882227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570523004557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":320,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0210570523004557"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2023.10.009","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH\u2013AEG\u2013SEPD\u2013SEOM\u2013GETECCU","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2023.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Espa\u00f1a S.L.U. and by Sociedad Espanola de Patologia Digestiva.","name":"copyright","label":"Copyright"}]}}